Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corporation (NASDAQ: DXR) is a medical instrumentation and biotechnology company focused on blood volume measurement, and its news flow centers on developments in this specialized diagnostic area. The company describes itself as the global leader in blood volume measurement technology, with approximately 50 years of experience and a patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic platform.
News about Daxor frequently highlights regulatory milestones, such as FDA 510(k) clearance for its next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer (Daxor BVA™). Announcements also cover commercial expansion, including adoption of its BVA platform and ezBVA Lab Service by health systems, academic medical centers and cardiology practices, as well as deployments of on-site analyzers for immediate blood volume assessment.
Investors and clinicians following DXR can expect updates on clinical research that evaluates BVA-guided care in conditions like heart failure, LVAD implantation, cardiac amyloidosis, sepsis and COVID-19. Company releases summarize peer-reviewed studies and pilot trials that examine outcomes such as readmissions, survival, kidney injury and hospital length of stay when blood volume analysis is incorporated into care pathways.
Daxor’s news flow also includes participation in medical and investor conferences, where management presents corporate updates and showcases its technology to cardiovascular and critical care audiences, as well as institutional investors. For those tracking DXR, this news page offers a focused view of how the company’s blood volume analysis technology is progressing through regulatory clearance, clinical validation and market adoption over time.
Daxor Corporation (DXR) announced a registered direct offering involving 125,000 shares of common stock from the Company and 225,000 shares from the Estate of Joseph Feldschuh at $20.00 per share, generating gross proceeds of $7.0 million. The Company plans to allocate $2.5 million for working capital and corporate purposes. The offering is set to close around July 22, 2020. H.C. Wainwright & Co. is the exclusive placement agent.
Daxor Corporation (NYSE: DXR) has initiated a multicenter study at NYU Langone Health to utilize its BVA-100 blood volume analysis technology in hospitalized COVID-19 patients. The trial aims to assess volume derangements in these patients to enhance care and outcomes. The BVA technology is noted for its precise volume measurement capabilities, which could lead to individualized treatment and improved prognostic assessments. Previous studies have indicated that BVA-guided care may significantly lower mortality rates in critical care settings.
Daxor Corporation (NYSE: DXR) announced that CEO Michael Feldschuh will participate in Maxim Group and M-Vest’s COVID-19 Virtual Series on May 27, 2020. He will be a panelist in the session titled “Cell Therapy For ARDS – When Remdesivir Is Not Enough.” This conference aims to address important medical discussions amidst the pandemic. Daxor specializes in blood volume measurement technology, including the FDA-cleared BVA-100, which improves treatment strategies in various medical conditions, ultimately enhancing patient outcomes.
Daxor Corporation (NYSE: DXR) announced the publication of blood volume outcome data in the journal Circulation, using its BVA-100 device in a Yale University study on heart failure. This study demonstrates the significant role of blood volume changes in improving long-term heart failure outcomes. CEO Michael Feldschuh emphasized the BVA-100's status as the gold standard for accurate blood volume measurement, confirming its relevance in both research and clinical settings. The study's findings support the efficacy of Empagliflozin in heart failure treatment.